Results 171 to 180 of about 92,350 (272)

Clinical Features, Treatments, and Outcomes of an International Cohort of 96 Children with Takayasu Arteritis

open access: yesACR Open Rheumatology, Volume 8, Issue 11, November 2026.
Objective To characterize the clinical features, treatment, and outcomes of a large, international cohort of childhood‐onset Takayasu arteritis (cTAK). Methods Patients with a diagnosis of cTAK were identified in A Registry of Childhood Vasculitis and divided into subcohorts by era‐of diagnosis: pre‐biologic (PB; 1986–2006), early biologic (EB; 2007 ...
James Bistolarides   +29 more
wiley   +1 more source

Machine Learning to Predict Remission Between 6 and 24 Months in Rheumatoid Arthritis: Insights From JAK, an International Registry Collaboration

open access: yesArthritis &Rheumatology, Volume 78, Issue 11, Page 2232-2245, November 2026.
Objective To develop, externally validate, and simplify a machine learning model to predict remission between 6 and 24 months in patients with rheumatoid arthritis (RA) initiating tumor necrosis factor inhibitors, JAK inhibitors, interleukin‐6 inhibitors, abatacept, or rituximab using data from 11 international registries in the JAK‐pot collaboration ...
Zubeyir Salis   +22 more
wiley   +1 more source

Expert Perspectives: Defining and Managing Progressive Pulmonary Fibrosis in Systemic Sclerosis

open access: yesArthritis &Rheumatology, Volume 78, Issue 11, Page 2189-2202, November 2026.
Systemic sclerosis–associated interstitial lung disease (SSc‐ILD) is one of the leading causes of morbidity and mortality in SSc, affecting up to three‐quarters of patients. The disease course is highly heterogeneous, ranging from indolent, nonprogressive forms to rapidly progressive pulmonary fibrosis (PPF).
Devis Benfaremo   +7 more
wiley   +1 more source

Severe Thrombocytopenia Induced by Re‐Exposure to Piperacillin/Tazobactam: A Case Report in Critically Ill Patient With COVID‐19

open access: yesClinical Case Reports, Volume 14, Issue 11, November 2026.
ABSTRACT Drug‐induced thrombocytopenia is a condition where certain medications can significantly reduce the platelets in the blood. This can increase the risk of bleeding and bruising. We reported a case of a 73‐year‐old woman with multiple comorbidities who was admitted to the hospital with COVID‐19.
Abdullah F. Alharthi   +6 more
wiley   +1 more source

Lumps, Bumps, and Diagnostic Stumps: A Case Report of IgG4‐Related Disease

open access: yesClinical Case Reports, Volume 14, Issue 11, November 2026.
ABSTRACT IgG4‐related disease and idiopathic multicentric Castleman disease are rare conditions that can present with overlapping features, complicating diagnosis and delaying proper treatment.
Michael Miller   +4 more
wiley   +1 more source

Diagnostic Challenge of Multivessel Takayasu Arteritis—A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 11, November 2026.
ABSTRACT Progressive limb claudication, pulse deficits, marked inter‐arm blood pressure differences, and elevated inflammatory markers should prompt evaluation for Takayasu arteritis. Early vascular ultrasound followed by CTA or MRA enables timely diagnosis and treatment in settings with delayed access to specialist services, reducing the risk of ...
Khaleda Parvin   +6 more
wiley   +1 more source

Chimeric antigen receptor T‐cell therapy as a cure for large B‐cell lymphoma

open access: yesHemaSphere, Volume 10, Issue 11, November 2026.
Abstract Large B‐cell lymphoma (LBCL) is cured in most patients with first‐line chemoimmunotherapy; however, 30%–40% of patients will have relapsed or refractory (R/R) disease. Of these patients, those with refractory or early relapsed LBCL may receive chimeric antigen receptor (CAR) T‐cell therapy as their second‐line treatment if they are eligible ...
Danielle S. Wallace   +3 more
wiley   +1 more source

Clinical Impact of CTLA4 and LAG3 Single‐Nucleotide Polymorphisms in Multiple Myeloma Patients Treated With BCMA CAR T‐Cell Therapy

open access: yesHematological Oncology, Volume 44, Issue 6, November 2026.
ABSTRACT Chimeric antigen receptor (CAR) T‐cell therapy targeting B‐cell maturation antigen (BCMA) is a highly effective treatment option for patients with relapsed refractory multiple myeloma (RRMM). However, reliable biomarkers predicting long‐term treatment response remain elusive. Germline single‐nucleotide polymorphisms (SNPs) in immune checkpoint
Elisa Suter   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy